Page 60 - MemoriaER-Eng

TRANSVERSAL PLATFORMS

PROTEOmAb

PROTEOmAb is an energy metabolism phenotyping platform using protein array tech-

nology. It is located in CIBERER unit U713 UAM Severo Ochoa Molecular Biology Cen-
tre led by Dr. José María Cuezva. The group has ample experience in this methodol-

ogy that it has been offering as a service to the scientific community since 2012. It

offers a service comprising the quantitative analysis of energy metabolism proteins in
biological samples in a simple and reproducible manner using high-affinity and high-

specificity monoclonal antibodies (mAbs).

Methodology: The analysis can be done on collections of up to 1,000 different biop- í
sies, which allows establishing correlations with clinical parameters and parameters of

response to certain treatments. A reverse-phase protein microarray platform is used,

which allows quantifying the expression of energy metabolism proteins in biopsies of
normal and pathological tissues.

ó

PROTEOmAb services

• Identification and validation of molecular markers of the disease and of the re-
sponse to therapy.

•
Identification of new diagnostic markers.
ó
• Establishing correlations between biomarkers and disease progression.
í
• Establishing correlations between biomarkers and response to a treatment spe-
cific.

PROTEOmAb collaborations/services developed

Collaborations have been established with various NBRC groups and with other insti-

tutions:
13
20
T
R
• Dr. Lourdes Ruiz Desviat, Universidad Autnoma de Madrid, CIBERER U746 and PO
Dr. Barry Michel, Mayo Clinic, Rochester, USA. Pathology studied: Propionic aci- E
L R
demia.
A
NU
• Dr. Francesc Cardellach Lpez, Hospital Clnic de Barcelona, CIBERER U722. N
A
Pathology studied: All myositis variants: dermatomyositis, polymyositis and /
myositis with inclusion bodies.
ER
ER
• Dr. Miguel A. Martn Casanueva, 12 de Octubre Hospital Research Institute (i+12), B
CI
Madrid, CIBERER U723. Pathology studied: Mitochondriopathies due to Complex

60
I deficiency.